Study Supports GlucoTrack’s Blood Glucose Monitoring Implant

By Karen Roman

GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life implantable continuous glucose monitors like the devices the company develops.

The article came out on April 7, 2026, and is the result of a partnership between GlucoTrack and United Kingdom‑based scientific organization TTP, and is available online here.

“Peer-reviewed characterization of foundational sensor data is an important step as we continue to advance our development program and work toward clinical and regulatory milestones,” said Dr. Paul Goode, GlucoTrack’s President and CEO.

READ MORE

Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment

Never Miss our Weekly Highlights HERE

Contact:

Exec Edge

[email protected]

Click HERE to follow us on LinkedIn

View Comments